Navigation Links
Isis Reports Financial Results and Highlights for First Quarter 2012
Date:5/8/2012

, and are designed to provide long-term control in patients who cannot control their glucose levels with existing therapies.  With type 2 diabetes being the most rapidly growing epidemic worldwide, we believe bringing forward novel medicines to add to the treatment paradigm for these patients is a wise investment," continued Ms. Parshall.  

"In summary, we have begun another productive year in which we expect to report data on many of the drugs in our pipeline, initiate larger, longer studies for our Factor XI and TTR drugs, and continue to move promising new drugs into our pipeline.
We look forward to KYNAMRO commercialization and bringing this important new medicine to patients in great need," concluded Ms. Parshall. 

Corporate and Drug Development Highlights

  • Genzyme submitted a new drug application for KYNAMRO in the United States for homozygous FH patients.
  • Dr. Raul Santos presented data from the long-term extension study of KYNAMRO at the International Symposium on Atherosclerosis.  The data highlight the long-term safety and efficacy of KYNAMRO in patients who have been treated with KYNAMRO.
  • Isis initiated a Phase 2 study on ISIS-APOCIIIRx in patients with elevated triglycerides and a Phase 1 study on ISIS-STAT3Rx in patients with cancer.
  • Isis reported data from a Phase 1 study of ISIS-TTRRx showing that ISIS-TTRRx produced statistically significant reductions in TTR protein.
  • Isis formed a new strategic alliance with Biogen Idec to develop and commercialize ISIS-SMNRx to treat Spinal Muscular Atrophy (SMA).  Isis received a $29 million upfront payment and is eligible to receive up to an additional $270 million in a license fee and milestone payments, and double-digit royalties on sales of ISIS-SMNRx.
  • Isis received Orphan Drug Designation for ISIS-SMNRx in Europe for the treatment of SMA.
  • OncoGenex reported preliminary positive Phase 1 d
    '/>"/>

  • SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Vanda Pharmaceuticals Reports First Quarter 2012 Results
    2. Landauer, Inc. Reports Fiscal 2012 Second Quarter Results
    3. Halozyme Reports First Quarter 2012 Financial Results
    4. MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results
    5. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
    6. IRIDEX Reports 2012 First Quarter Results
    7. Cambrex Reports First Quarter 2012 Results
    8. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
    9. Cumberland Pharmaceuticals Reports First Quarter 2012 Financial Results
    10. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
    11. Neuland Labs Reports Financial Results For Fiscal Year 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
    (Date:8/29/2014)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... to the medical, research and veterinary markets, announced today ... Officer, will present at the CL King 12 th ... 9, 2014 at 12:30 p.m. ET. The conference will ... New York City . ...
    (Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
    Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
    (Date:8/30/2014)... 2014 According to Bloomberg , ... requires Takeda Pharmaceutical Co. and Eli Lilly & Co. ... that the drugmakers concealed information about a risk of ... case, Allen v. Takeda Pharmaceuticals North America Inc. (12-cv-00064), ... of Louisiana (Lafayette).* , According to Bloomberg, Takeda and ...
    (Date:8/30/2014)... (PRWEB) August 30, 2014 ... a Spa-on-Wheels which offers the complete spa experience ... inviting lighting and the most important ingredient of ... "the dedicated licensed pro's! People will enjoy the ... continues Kaplan-Pelle. The website reads, "Step into the ...
    (Date:8/30/2014)... Plains, NJ (PRWEB) August 30, 2014 ... first facilities in New Jersey and even in the ... technology that takes inches off of patients’ waists with ... freezing cells in small sections, Vanquish is more inclusive ... pain. Patients lay comfortably under panels about one ...
    (Date:8/30/2014)... Jackson, Tenn. (PRWEB) August 30, 2014 ... people around the country for the past several ... the Tennessee Hyperbaric Center have announced a scholarship ... PTSD. This announcement follows a meeting held this ... , In recent years, reporters have shed light ...
    (Date:8/30/2014)... Insomnia causes disturbances in every aspect of life. ... developed insomnia and the steps often used to return back ... to the show at this link: Dr. Carol Francis ... 30, and will be podcasted at this link (Click ... DrCarolFrancisTalkRadio.com. , "Insomnia causes countless unrecognized complications. Weight ...
    Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Decision to Uphold $9 Billion Actos Award 2Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2
    ... and Mehmet Oz, MD, Launch Daily Syndicated ... Newspaper Column, ... E? Who better to keep the health momentum going than the YOU ... expert for The Oprah Winfrey Show. King Features Syndicate and,RealAge.com announce the ...
    ... Texas University of Texas Medical Branch at Galveston ... weapon against respiratory syncytial virus, the most common cause ... an effort to find an effective antiviral therapy for ... molecule to interfere with the genetic machinery that RSV ...
    ... Response Essentially Met but Donations Still Needed to Prepare,for ... WASHINGTON, May 5 The American Red Cross,today ... the Southeastern,Virginia tornadoes but donations to its Disaster Relief ... the next disaster, particularly with the,beginning of hurricane season ...
    ... Exclusive License for Pulse!! Virtual Learning Platform for ... Clinical Skills and Decision Making Training, ... developer of,game-based technology solutions for training, experimentation and,decision-making analysis, ... System for the exclusive, worldwide rights to Pulse!! the,Virtual ...
    ... Herley Industries, Inc.,(Nasdaq: HRLY ) announced today ... U.S. Government on all existing criminal and civil,claims. These ... had been scheduled for trial on May 5, 2008 ... control oscillators in January 2001 and,two contracts involving the ...
    ... a previously unrealized mechanism by which the epidermal growth ... cancer cells through a kinase-independent mechanism. The research, published ... journal Cancer Cell, provides a rationale for the less ... at interfering with kinase activity and suggests new directions ...
    Cached Medicine News:Health News:Need a Daily Dose of Good Health Advice to Keep You Going? 2Health News:Need a Daily Dose of Good Health Advice to Keep You Going? 3Health News:New agent strikes at respiratory syncytial virus replication 2Health News:Generous Donors Allow Red Cross to Respond Swiftly and Effectively to Southeastern Virginia Tornadoes 2Health News:Generous Donors Allow Red Cross to Respond Swiftly and Effectively to Southeastern Virginia Tornadoes 3Health News:Game-Based Technology to Meet Demand for Improved Medical Teaching and Training 2Health News:Game-Based Technology to Meet Demand for Improved Medical Teaching and Training 3Health News:Herley Announces Settlement Agreement with U.S. Government 2Health News:Herley Announces Settlement Agreement with U.S. Government 3Health News:EGFR protects cancer cells from starvation via a kinase-independent mechanism 2
    ... WideBiter Punch series facilitates fast and effective ... smooth, anatomically shaped meniscal rim. The flat, ... to access even the tightest joint spaces. ... Inc., 20 years of engineering experience in ...
    ... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
    ... series facilitates fast and effective resection of ... shaped meniscal rim. The flat, crescent-shaped tip ... even the tightest joint spaces. Made in ... years of engineering experience in arthroscopy hand ...
    ... facilitates fast and effective resection of meniscal ... meniscal rim. The flat, crescent-shaped tip has ... the tightest joint spaces. Made in the ... of engineering experience in arthroscopy hand instrument ...
    Medicine Products: